A study conducted by Kaiser Permanente Southern California has shown that proactive measures can reduce hip fracture rates by an average of 37.2 percent — and as much as 50 percent — among those at risk. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal.
The [...]

Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS® (peginterferon alfa-2a (40KD)) and COPEGUS® (ribavirin) to 72 weeks, according to new studies being presented at AASLD this week in San Francisco.
“Seeking solutions for difficult-to-treat hepatitis C with the currently-available agents is a priority,” [...]

A new, independently-conducted study being presented at AASLD shows that PEGASYS® (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan Safety Tolerability Study
Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M. Migliavacca Center for Liver Disease [...]

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS - News) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting [...]

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS - News) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting [...]

New clinical data from four Phase 2 clinical trials of the investigational hepatitis C protease inhibitor telaprevir (VX-950) to be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco support a broad profile for telaprevir in the treatment of chronic genotype 1 hepatitis C [...]

Four-week Phase 2 clinical trial data show that GI-5005, GlobeImmune’s hepatitis C virus (HCV) targeted molecular immunogen (Tarmogen®), doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response (RVR) rate in naïve patients with high viral load. The study compared GI-5005 plus standard of care (SOC) — pegylated-interferon plus ribavirin [...]

Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS® (peginterferon alfa-2a (40KD)) and COPEGUS® (ribavirin) to 72 weeks, according to new studies being presented at AASLD this week in San Francisco.
“Seeking solutions for difficult-to-treat hepatitis C with the currently-available agents is a priority,” [...]

A new, independently-conducted study being presented at AASLD shows that PEGASYS® (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan Safety Tolerability Study
Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M. Migliavacca Center for Liver Disease [...]

While the market for initial public offerings has shut down in all industries, with no deals in the United States in nearly three months, biotechnology companies desperate for capital will likely be waiting in line far longer than others when it does re-open.
Once an industry coveted by investors, biotech has not seen an IPO since [...]